INDIANAPOLIS, April 18, 2011 /PRNewswire/ —
First quarter 2011 revenue grew 6 percent to $5.8 billion,
driven by increased demand in international markets.Company
delivered first quarter earnings per share of $.95 (reported), or
$1.24 (non-GAAP).2011 non-GAAP earnings per share guidance
range unchanged at $4.15 – $4.30; reported earnings per share
guidance range of $3.86 – $4.01 now reflects Q1 restructuring
charge.
Eli Lilly and Company (NYSE:
LLY) today announced financial results for the first quarter of
2011.$ in millions, except per share data
First Quarter
%20112010
GrowthTotal Revenue – Reported
$5,839.2$5,485.5
6%Net Income – Reported
1,055.91,248.1
(15)%EPS – Reported
0.951.13
(16)%Net Income – non-GAAP
1,374.91,297.6
6%EPS – non-GAAP
1.241.18
5%Financial results for 2011 and 2010 are presented on both a
reported and a non-GAAP basis. Reported results were prepared in
accordance with generally accepted accounting principles (GAAP) and
include all revenue and expenses recognized during the period.
Non-GAAP results exclude the items described in the reconciliation
tables. The non-GAAP results are presented in order to provide
additional insights into the underlying trends in the company’s
business. The company’s 2011 financial guidance is also being
provided on both a reported and a non-GAAP basis.
“Lilly started the year by delivering solid financial results as
we continue to advance the next wave of potential new medicines in
our pipeline,” said John C. Lechleiter, Ph.D., Lilly’s chairman,
president and chief executive officer. “Growth in international
markets and the strong performance of Cymbalta, Alimta and our
animal health business drove volume-based revenue growth of six
percent, des
‘/>”/>
